Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes.
Zhang J-Y. et al, (2022), Nat Commun, 13
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.
Foster WS. et al, (2022), Cell Rep Med
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe A. et al, (2022), JCI Insight, 7
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A. et al, (2021), Lancet, 398, 981 - 990